J&J
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
Nucleome Therapeutics Collaborating With J&J to Identify Target Genes in Autoimmune Diseases
The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Johnson & Johnson to Use BillionToOne's Fetal Antigen Assay in Phase III Clinical Trial
The US Food and Drug Administration approved an investigational device exemption to allow the UNITY Fetal Antigen CTA to be used in this trial.
The resource contains Illumina whole-genome sequencing data from UK Biobank participants and is available to approved researchers worldwide.